Tirzepatide

Summary: Tirzepatide is Eli Lilly's once-weekly injectable dual GIP and GLP-1 receptor agonist, FDA-approved as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Tirzepatide is a once-weekly injectable peptide that activates two gut hormone receptors at once, GIP and GLP-1. Eli Lilly makes it. The FDA approved it as Mounjaro for type 2 diabetes in May 2022 and as Zepbound for chronic weight management in November 2023 ^[1][2]. It is the first dual-incretin agonist on the US market, and in head-to-head trials it produces larger reductions in A1c and body weight than semaglutide, the previous benchmark.

This page is the canonical overview. The mechanism, the trials, the doses, the side effects, the cost, and how it compares to semaglutide. For specific dosing questions, conversion math, side effect deep-dives, and brand comparisons, the dedicated sub-articles on this site cover them in detail.

What tirzepatide is, in one paragraph

Tirzepatide is a 39 amino acid synthetic peptide, structurally derived from the natural GIP hormone, modified with a C20 fatty acid side chain that binds albumin and extends its half-life to roughly five days. That half-life is why it dosed once weekly. The molecule activates the GIP receptor and the GLP-1 receptor simultaneously, which is why the drug class is called a dual GIP/GLP-1 receptor agonist or sometimes a twincretin. Semaglutide, by contrast, only hits the GLP-1 receptor. The second receptor is the difference that explains most of tirzepatide's stronger efficacy numbers.

Brand names: Mounjaro and Zepbound

Eli Lilly sells the same molecule under two brand names because the FDA approved it twice, for two different conditions.

The active ingredient, the pen device, and the dose strengths (2.5, 5, 7.5, 10, 12.5, 15 mg) are identical between the two brands ^[1][2]. The only differences are the label indication, the patient population the prescribing physician must document, and the insurance coverage path. Insurers that cover Mounjaro for T2D often refuse to cover Zepbound for obesity, which is why the two brands exist as separate SKUs even though the syringe content is the same.

Outside the US, Lilly markets tirzepatide as Mounjaro in many countries for both diabetes and weight loss, since the brand separation is a US-specific commercial choice.

How tirzepatide works

Tirzepatide is a peptide, not a small molecule. It does not cross the blood-brain barrier directly, but its receptors are expressed on neurons in regions of the hypothalamus and brainstem that the barrier exposes, so peripheral activation of those receptors changes central appetite signaling. That is the mechanism for the satiety effect.

In the pancreas, GLP-1 receptor activation triggers glucose-dependent insulin release from beta cells and suppresses inappropriate glucagon release from alpha cells. Glucose-dependent means insulin only rises when blood sugar is elevated, which is why GLP-1 drugs rarely cause hypoglycemia on their own. GIP receptor activation amplifies the insulin response further and may have direct effects on fat tissue insulin sensitivity, which is one hypothesis for why adding GIP agonism to GLP-1 agonism produces more weight loss than GLP-1 alone.

In the stomach, both receptors slow gastric emptying. Food stays in the stomach longer, so satiety signals last longer, and post-meal glucose excursions are blunted. The slowed emptying is also the mechanism behind tirzepatide's main side effects: nausea, vomiting, and constipation.

In the brain, peripheral receptor activation feeds into the arcuate nucleus and the nucleus of the solitary tract, regions that regulate hunger and meal termination. Patients describe the effect as the disappearance of "food noise," the constant background pull toward eating that drives a lot of unplanned consumption.

FDA-approved indications

Mounjaro is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus ^[1]. It is not indicated for type 1 diabetes. It is not first-line in every guideline; the American Diabetes Association now recommends it as an option for people with T2D who need both glucose control and meaningful weight loss, which is most of them.

Zepbound is approved for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease ^[2]. In December 2024 the FDA expanded the Zepbound label to include moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial. As of 2026 Zepbound is also being studied for heart failure with preserved ejection fraction, MASH (metabolic dysfunction-associated steatohepatitis), and chronic kidney disease.

Off-label use is widespread. Doctors prescribe Mounjaro for weight loss in patients without diabetes, and Zepbound for diabetes patients whose insurance refuses Mounjaro. The molecule is the same, the off-label cases are clinically sensible, but the insurance paperwork is brand-specific.

The key trials

Two trial programs put tirzepatide on the map. SURPASS for diabetes, SURMOUNT for obesity. Both ran with Lilly funding, both published in NEJM, both showed efficacy numbers that exceeded the existing GLP-1 standard.

SURPASS-2: tirzepatide beats semaglutide in T2D

SURPASS-2 was the head-to-head trial that made tirzepatide a commercial success. The study enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin, randomizing them to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, versus semaglutide 1 mg (the highest dose then approved for diabetes) ^[4]. After 40 weeks:

• Tirzepatide 15 mg reduced A1c by 2.30 percentage points.
• Semaglutide 1 mg reduced A1c by 1.86 percentage points.
• Tirzepatide 15 mg produced 11.2 kg of body weight loss.
• Semaglutide 1 mg produced 5.7 kg of body weight loss.

The A1c difference was statistically and clinically significant. The weight difference was roughly double. Side effect profiles were comparable, dominated by mild-to-moderate GI symptoms in both groups. SURPASS-1, 3, 4, and 5 confirmed tirzepatide's glycemic efficacy versus placebo, insulin degludec, and insulin glargine in different patient populations.

SURMOUNT-1: the obesity trial

SURMOUNT-1 was the trial that justified the Zepbound approval. The study enrolled 2,539 adults with obesity (BMI 30+) or overweight (BMI 27+) with a weight-related comorbidity, but without diabetes, randomizing them to once-weekly tirzepatide 5 mg, 10 mg, or 15 mg, or placebo, for 72 weeks alongside lifestyle counseling ^[3]. The mean percentage weight loss from baseline:

• Tirzepatide 5 mg: 15.0%
• Tirzepatide 10 mg: 19.5%
• Tirzepatide 15 mg: 20.9%
• Placebo: 3.1%

In absolute terms, the 15 mg arm averaged roughly 22 kg (48 lb) of weight loss over 72 weeks. About 57% of participants on tirzepatide 15 mg lost 20% or more of their starting body weight, a magnitude previously only seen with bariatric surgery.

SURMOUNT-2 extended the data to people with T2D and obesity. SURMOUNT-3 added intensive lifestyle intervention. SURMOUNT-4 looked at what happens when you stop the drug (weight comes back, fast). SURMOUNT-OSA covered sleep apnea. The trial program is one of the most thoroughly characterized in modern obesity medicine.

Dosing and titration

Tirzepatide is dosed once weekly by subcutaneous injection, on the same day each week, at any time of day, with or without food ^[1][2]. The titration schedule is the same for both brands:

The 2.5 mg starting dose is not intended to be therapeutic. Its job is to let the gut adapt to slowed gastric emptying before the dose rises high enough to drive meaningful efficacy. People who skip the titration and jump to therapeutic doses almost always quit early because the GI side effects overwhelm them. The maximum dose is 15 mg for both indications. Many patients find their effective dose at 10 mg and stay there.

If you miss a dose, take it as soon as possible if there are still at least 4 days until the next scheduled dose. If less than 4 days remain, skip the missed dose and resume the regular schedule. Never inject two doses within 72 hours of each other.

The pen injects through a 32-gauge needle into the abdomen, thigh, or upper outer arm. Rotation between sites matters. The full injection takes about 10 seconds; you press the button and wait for the second click. Lilly also distributes single-dose vials for compounding workarounds during shortages, though as of 2026 the FDA has removed tirzepatide from the official shortage list and most large compounders have wound down operations.

Side effects

The side effect profile is dose-dependent and overwhelmingly gastrointestinal. The pivotal trials reported the following common adverse events ^[1][2][3][4]:

• Nausea: 12% to 31% of patients depending on dose, usually mild to moderate, peaks in the first weeks at each dose escalation, then fades.
• Diarrhea: 12% to 23%.
• Vomiting: 5% to 13%.
• Constipation: 6% to 11%.
• Decreased appetite: 5% to 11%, which most patients consider a desired effect, not a side effect.
• Dyspepsia, abdominal pain, fatigue, injection-site reactions: each in the 5% to 10% range.

Most GI side effects resolve within a few weeks of starting or escalating. Eating smaller meals, avoiding very fatty or greasy food, and staying hydrated reduces severity. A small fraction of patients cannot tolerate the drug even at 2.5 mg and discontinue.

Serious risks the label flags:

• Thyroid C-cell tumors: rodent studies showed dose-dependent C-cell tumors with tirzepatide and other GLP-1 drugs. Whether this translates to humans is unknown. The label carries a boxed warning and contraindicates the drug in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: acute pancreatitis has been reported in trials. Persistent severe abdominal pain that radiates to the back is the warning sign. Stop the drug and seek care.
• Gallbladder disease: rapid weight loss raises gallstone risk. Tirzepatide adds an independent signal on top of that.
• Hypoglycemia: rare on tirzepatide alone, but the risk rises when combined with insulin or sulfonylureas. Those background medications often need dose reduction at the start of tirzepatide.
• Acute kidney injury: usually secondary to dehydration from severe nausea and vomiting. Stay hydrated; if you cannot keep fluids down, contact your prescriber.
• Diabetic retinopathy complications: in patients with pre-existing retinopathy, rapid glucose improvement can transiently worsen the eye disease. Eye exams matter at baseline and during the first year.
• Suicidal ideation: post-marketing reports exist, the FDA reviewed the signal in 2024 and did not find a causal link, but the label requires monitoring for mood changes.

Who tirzepatide is for, who it is not for

Tirzepatide is appropriate for:

• Adults with type 2 diabetes whose A1c remains above goal on metformin or other oral agents.
• Adults with type 2 diabetes who also need significant weight loss.
• Adults with obesity (BMI 30+) or overweight (BMI 27+) with a comorbidity, who have tried lifestyle changes and need pharmacologic help.
• Adults with obstructive sleep apnea and obesity (the new Zepbound indication).

Tirzepatide should not be used by:

• Anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
• People with a history of pancreatitis (relative contraindication; weigh risk).
• People with severe gastrointestinal disease, including gastroparesis. Slowed gastric emptying on top of pre-existing gastroparesis can cause severe symptoms.
• People with type 1 diabetes. Tirzepatide is not approved for, and not effective in, T1D.
• Pregnant or breastfeeding women. The drug has not been adequately studied in pregnancy; animal data suggest fetal risk. Women of reproductive age using oral contraceptives should know that tirzepatide reduces oral contraceptive absorption for several weeks after starting or escalating doses, due to slowed gastric emptying. The label recommends switching to a non-oral contraceptive or adding a barrier method for 4 weeks after each dose change.
• Children under 18. Pediatric trials are underway, but no current approval covers them.

Cost and access

The list price for both Mounjaro and Zepbound in the US is approximately $1,060 per month for the brand pens, before insurance and savings programs ^[5]. Lilly offers a savings card that can drop the price to $25 per month for commercially insured patients whose plans cover the drug, and a higher subsidy for those whose plans do not. Cash-pay patients without insurance face the full list price.

In response to demand and shortage pressure, Lilly launched LillyDirect in 2024, which ships single-dose vials of Zepbound directly to patients at a reduced cash price ($349 for 2.5 mg, $499 for 5 mg, $599 for 7.5 mg, $699 for 10 mg, $749 for 12.5 mg and 15 mg per month as of early 2026). The vials require self-drawing with a syringe instead of the pen device, which lowers Lilly's manufacturing cost.

Compounded tirzepatide flourished during the 2023 to 2024 shortage. With tirzepatide off the FDA shortage list since late 2024, large compounders are no longer permitted to mass-produce it, though small 503A pharmacies can still compound for specific patient needs in limited cases. Many of the cash-pay telehealth programs that built on compounded tirzepatide have pivoted to LillyDirect vials, semaglutide compounding, or other peptides.

International pricing is a different story. In the UK, Mounjaro lists at around 150 pounds per month. In Australia and Canada, prices fall between US and UK levels. None of those markets has the US pharmacy benefit manager middle layer that drives American list prices upward.

Tirzepatide versus semaglutide

The most useful direct comparison for patients deciding between the two top GLP-1 class drugs.

The short version: tirzepatide produces more weight loss and slightly better glucose control. Semaglutide has more cardiovascular outcome data and the only currently-approved oral GLP-1 (Rybelsus, for diabetes). For most patients without cardiovascular disease, tirzepatide's efficacy edge matters more. For patients with established atherosclerotic cardiovascular disease, semaglutide currently has the labeled cardiovascular benefit; SURPASS-CVOT is expected to provide tirzepatide's data later this decade.

Is tirzepatide a GLP-1? Is it a peptide?

Quick answers to the questions search engines see most often.

Tirzepatide activates the GLP-1 receptor, so in a loose colloquial sense people call it a "GLP-1." Technically it is a dual GIP and GLP-1 receptor agonist, also called a twincretin. It belongs to the same broad therapeutic class as semaglutide, liraglutide, and dulaglutide, but it has a second mechanism those drugs lack.

Tirzepatide is a peptide, a 39 amino acid synthetic molecule. Like other peptide drugs, it cannot be taken orally in its current form because stomach acid and intestinal enzymes would digest it before absorption. It is given by subcutaneous injection. Lilly is studying oral and small-molecule GIP/GLP-1 dual agonists (orforglipron, retatrutide), but those are different molecules in earlier-stage trials.

What to expect in the first year on tirzepatide

Most patients see noticeable appetite suppression within the first one to two weeks of starting, even at the 2.5 mg initiation dose. Weight loss typically begins in week two or three. The first dose escalation to 5 mg often brings a new wave of nausea that lasts a few days then settles. Each subsequent escalation brings a smaller version of the same pattern.

By month three (around the 7.5 mg or 10 mg dose, depending on titration speed), most non-diabetic patients have lost 6% to 10% of their starting body weight. By month six, 12% to 16%. By month twelve, 15% to 20% if they reached the 10 to 15 mg dose. People with diabetes lose somewhat less because their physiology starts further from baseline.

A1c starts dropping within two to four weeks, with full effect at the new dose visible by week eight. Patients on insulin or sulfonylureas often need to taper those background medications down during titration to avoid hypoglycemia.

The data on what happens after the first year is still maturing. SURMOUNT-4 showed that stopping the drug at week 36 in responders led to roughly 14% weight regain over the following year, suggesting tirzepatide is a chronic disease medication, not a short-term intervention. Most prescribers now plan for indefinite use, similar to how blood pressure medication is managed.

Common questions about tirzepatide

What is tirzepatide used for?

Tirzepatide treats type 2 diabetes (as Mounjaro) and chronic obesity or overweight with comorbidity (as Zepbound). It was also approved for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.

What are the brand names for tirzepatide?

Mounjaro (for type 2 diabetes, approved 2022) and Zepbound (for weight management, approved 2023). Both are made by Eli Lilly and contain identical active ingredient at identical doses.

Is tirzepatide a GLP-1?

Tirzepatide activates the GLP-1 receptor, so it shares mechanism with GLP-1 drugs. It also activates the GIP receptor, which makes it a dual GIP/GLP-1 agonist. Most clinicians refer to it informally as a GLP-1 even though it is more accurately a twincretin.

Is tirzepatide a peptide?

Yes. Tirzepatide is a 39 amino acid synthetic peptide derived from the natural GIP hormone, modified with a fatty acid side chain that extends its half-life to about five days and allows weekly dosing.

What drug class is tirzepatide?

Dual GIP and GLP-1 receptor agonist, sometimes called a twincretin or dual-incretin agonist. It is the first FDA-approved drug in this class.

How does tirzepatide work?

It activates GIP and GLP-1 receptors at the same time, which slows gastric emptying, increases satiety, suppresses appetite, stimulates glucose-dependent insulin release, and suppresses glucagon. The combined effect is significant weight loss and improved blood sugar control.

Does tirzepatide cross the blood-brain barrier?

Tirzepatide itself does not cross the blood-brain barrier in meaningful amounts. Its effects on appetite occur through GIP and GLP-1 receptors expressed on brain regions like the area postrema and arcuate nucleus that are accessible to peripheral peptides.

How is tirzepatide different from Ozempic?

Ozempic is semaglutide, a single GLP-1 receptor agonist. Tirzepatide adds the GIP receptor mechanism. In head-to-head trials (SURPASS-2), tirzepatide at 15 mg produced larger A1c reduction and roughly double the weight loss compared to semaglutide at 1 mg.

How much weight can you lose on tirzepatide?

In the SURMOUNT-1 trial, 72 weeks of tirzepatide 15 mg produced an average 20.9% body weight loss, roughly 22 kg or 48 lb. Real-world results vary; most patients who stay on the drug at therapeutic doses lose between 15% and 20% within a year.

How much does tirzepatide cost?

The US list price is around $1,060 per month for brand pens. Insurance copays and Lilly savings cards can drop that to $25 to $550 per month. LillyDirect vials cost $349 to $749 per month cash, depending on dose, as of early 2026.

How often do you take tirzepatide?

Once a week by subcutaneous injection on the same day each week. Time of day and meal timing do not matter.

How long does tirzepatide take to work?

Appetite suppression starts within the first week. A1c improvement is visible within two to four weeks. Meaningful weight loss starts in week two or three and accumulates steadily through month twelve.

Can you take tirzepatide forever?

There is no maximum duration in the FDA label. Trial data suggests stopping causes substantial weight regain and loss of glycemic control, so most prescribers plan for indefinite use. Long-term safety beyond five years is still being characterized.

Who should not take tirzepatide?

Anyone with a history of medullary thyroid cancer or MEN 2 syndrome, anyone with a known hypersensitivity to tirzepatide, people with type 1 diabetes, pregnant or breastfeeding women, and children. Caution applies to people with prior pancreatitis or severe GI motility disorders.

Related reading on this site

This article is the top-level overview. For deeper coverage of specific topics, the dedicated pages on this site cover dosing math (how many mL is each dose, what mg you draw for which volume), side effect timelines and management, brand-versus-compounded considerations, insurance and savings program details, interactions with specific medications and conditions, and head-to-head comparisons against semaglutide and other peptides.